Clinical Trials

ABEC Expands Process Sciences Capabilities To Accelerate Bioprocess Development And Scale Up

 ABEC, a global leader in bioprocess engineering solutions, announced the expansion of its Process Sciences group, expanding its ability to ...

 May 08, 2026 | News

Taimei Technology And C&R Research Partner To Advance AI Driven Clinical Trial Operations In South Korea

Taimei Technology (HK.02576), a leading AI-powered drug clinical development platform company, and C&R Research (A359090), a top-tier CRO in South Kore...

 May 08, 2026 | News

Alebund Completes Global Phase III Enrollment For AP301 In Hyperphosphatemia Trial

Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies...

 May 07, 2026 | News

Cellenkos Advances CK0802 Into Phase 1b 2a Trial Following FDA Clearance For Steroid Refractory GVHD

Multicenter, open-label study will evaluate the safety and preliminary efficacy of CK0802, a first-in-class, off-the-shelf Treg therapy, in patients with s...

 May 06, 2026 | News

EnGeneIC Doses First Patient In Trial Targeting Recurrent Glioblastoma

EnGeneIC announced that the first patient has been dosed in its clinical trial evaluating EnGeneIC’s investigational EGFR-targeted EDV™ (EnGene...

 May 05, 2026 | News

Australia Approves First RNAi Therapy For Familial Chylomicronemia Syndrome

– REDEMPLO is the first and only medicine approved for use in the treatment of FCS in Australia, and is authorized for both genetically confirmed a...

 May 05, 2026 | Report

Huahui Health And BeOne Medicines Forge Global Deal For Trispecific Antibody HH160

Huahui Health announced that it has entered into a global exclusive option, license and collaboration agreement with BeOne Medicines for HH160, a...

 May 04, 2026 | News

Restore Vision Reports Encouraging Phase I II Data For RV 001 Gene Therapy In Retinitis Pigmentosa

Phase I/II clinical trial interim results, out to 168 days, from the two RV-001 dosing cohorts with advanced Retinitis Pigmentosa are presented at key Ma...

 May 04, 2026 | News

Lakewood Amedex Advances Nu 3 Bisphosphocin Candidate With Strong AMR Resistance Profile

Nu-3 represents a novel class of potent, fast-acting, broad-spectrum antimicrobials called Bisphosphocins® Lakewood-Amedex Biotherapeutics Inc., (NASD...

 May 04, 2026 | News

Sonire Therapeutics Initiates SUNRISE II Trial To Advance Non Invasive HIFU Therapy For Pancreatic Cancer In The United States

SUNRISE-II feasibility trial marks the company's entry into U.S. clinical development, advancingminimally invasive, anesthesia-free treatment approach Son...

 May 04, 2026 | News

Formosa Pharmaceuticals And SERI Partner To Advance Next Generation Ophthalmic Therapies

    The collaboration aims to address significant unmet needs in the treatment of corneal and ocular surface diseases. By combining innovative ...

 May 01, 2026 | News

Chongqing Claruvis Pharmaceutical Secures NMPA Approval For Retoxin As First Recombinant Botulinum Toxin

Chongqing Claruvis Pharmaceutical Co., Ltd. recently announced that the China's National Medical Products Administration (NMPA) has approved its Retoxin&re...

 April 30, 2026 | News

C-Ray Therapeutics Activates FDA DMF For Copper 64 Radiolabelling To Enable Global IND And NDA Submissions

DMF No. 43568 is now active and available for reference in global IND and NDA submissions C-Ray Therapeutics (Chengdu) Co., Ltd., announced that its Type ...

 April 30, 2026 | News

IMG Pharmaceutical Co Ltd To Acquire Matsumoto Pharmaceutical Co Ltd To Strengthen Integrated Healthcare Platform

IMG Pharmaceutical Co., Ltd. ("IMG Pharma"), a majority-owned subsidiary of IMG Japan, the Group's holding company, announced that it has entered into a de...

 April 29, 2026 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close